Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
Conclusion: Our real-world data suggests that first line use of ICI combined with chemotherapy demonstrates better cost-effectiveness and similar survival outcomes for mUC patients, when compared with subsequent ICI therapy after chemotherapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Insurance | Study